Information Provided By: 
Fly News Breaks for February 27, 2018
CLVS
Feb 27, 2018 | 09:30 EDT
SunTrust analyst Peter Lawson lowered his price target on Clovis to $85 after the company's Q4 earnings, saying that since the revenues of Rubraca were "essentially flat", the Street was likely to reset growth expectations. The analyst adds that he has pushed back his view of commercialization in prostate and additional settings, but still believes the stock is "attractively positioned with reset revenues, and potentially positive news flows in the near term". Lawson keeps his Buy rating on Clovis.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
